or Try an Advanced Search...

    Tlr7 Stocks List

    Symbol Grade Name % Change
    DVAX F Dynavax Technologies Corporation -2.54
    URGN F UroGen Pharma Ltd. -1.77
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Antineoplastic Drugs Asthma Autoimmune And Inflammatory Disease Bladder Cancer Botulinum Toxin Cancer Carcinoma Chemotherapy Chronic Obstructive Pulmonary Disease Hepatitis B Immunotherapy Inflammatory Diseases Interstitial Cystitis Medicine Novel Products Oab Overactive Bladder Platform Technologies Pulmonary Disease

    Related ETFs - A few ETFs which own one or more of the above listed Tlr7 stocks.

    Symbol Grade Name Weight
    GERM B ETFMG Treatments Testing and Advancements ETF 3.7
    PBE C PowerShares Dynamic Biotech & Genome 2.62
    IZRL D ARK Israel Innovative Technology ETF 2.15
    IDNA C iShares Genomics Immunology and Healthcare ETF 1.85
    PSCH B PowerShares S&P SmallCap Health Care Portfolio 1.32
    View all Tlr7 ETFs...
    Compare ETFs
    Compare GERM to IDNA Compare GERM to PSCH Compare IZRL to IDNA

        Tlr7 Stocks Recent News

        Date Stock Title
        May 10 DVAX Dynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ...
        May 10 URGN UroGen Pharma Q1 2024 Earnings Preview
        May 10 DVAX Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
        May 10 DVAX Dynavax Technologies First Quarter 2024 Earnings: Misses Expectations
        May 9 DVAX Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Call Transcript
        May 9 DVAX Dynavax Technologies Corp (DVAX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue ...
        May 9 DVAX Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
        May 8 DVAX Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
        May 8 DVAX Dynavax drops 6% as quarterly results miss on both lines
        May 8 DVAX Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
        May 8 DVAX Dynavax GAAP EPS of -$0.07 misses by $0.04, revenue of $50.79M misses by $4.19M
        May 8 DVAX Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
        May 7 DVAX Dynavax Q1 2024 Earnings Preview
        May 5 URGN New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
        May 4 URGN UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Antineoplastic Drugs Asthma Autoimmune And Inflammatory Disease Bladder Cancer Botulinum Toxin Cancer Carcinoma Chemotherapy Chronic Obstructive Pulmonary Disease Hepatitis B Immunotherapy Inflammatory Diseases Interstitial Cystitis Medicine Novel Products Oab Overactive Bladder Platform Technologies Pulmonary Disease
        Tlr7

        Browse All Tags